←
Anusha Kalbasi282 posts
Anusha Kalbasi avatar

Anusha Kalbasi

@xrtcell

cancer immunology - sarcoma - melanoma - radiation oncology - kalbasilab.org @stanford

◷ Joined May 2012▧ 6 Photos and videos
Everett Moding, MD, PhD avatar
⟳ Anusha Kalbasi retweeted
Everett Moding, MD, PhD@everettmoding·Sep 9

Soft tissue sarcomas (#STS) have few recurrent mutations, making ctDNA testing a challenge. In our new paper in @JCO_ASCO, we show that personalized ctDNA analysis achieves high detection rates and can track treatment response in localized STS. 🧵 (1/11) doi.org/10.1200/JCO-26-00769

Anusha Kalbasi avatar
Anusha Kalbasi@xrtcell·Jul 7

Way to go Kayla, so well-deserved!

Feeling incredibly thankful to be awarded an NIH F30 Fellowship to continue my PhD work in cancer immunology. And grateful for my PI @xrtcell and my amazing lab for their support!

Pauline Funchain avatar
⟳ Anusha Kalbasi retweeted
Pauline Funchain@FunchainMD·Jun 1

Highly anticipated data with first in class modified TIL therapy that does not use IL2, has lower dose lymphodepleting chemo - single arm ph1/2 OBX-115 in refractory metastatic melanoma #ASCO26 @DrBetofMDPhD @StanfordCancer ORR 67% w 2 CR (!!) DoR not reached (1+ to 14+m)

Post attachmentPost attachmentPost attachmentPost attachment
Kyle G Daniels avatar
⟳ Anusha Kalbasi retweeted
Kyle G Daniels@ScienceKyle·May 14

🚨What if we could reliably program macrophage polarization state?🚨 biorxiv.org/content/10.64898… Macrophages are highly plastic immune cells that perform critical functions by polarizing into distinct cellular states. The polarization state of macrophages can substantially influences the progression of cancers, infections, and autoimmunity. (1/11)

Post attachment
Anusha Kalbasi avatar
Anusha Kalbasi@xrtcell·Mar 31

In a small ph1 (n=14) we cannot over-interpret outcomes. But scRNAseq shows BO-112+RT more effectively depletes malignant cells. LC and DFS (and ctDNA @EverettModing) in pts with high risk ext/trunk UPS/MFS were promising & support further clin dev (if tox is fully mitigated). /8

Anusha Kalbasi avatar
Anusha Kalbasi@xrtcell·Mar 31

In longitudinal tumor specimens from pts we saw RT depletes T cells but not myeloid cells. BO-112 engages myeloid cells toward Ag presenting & IFN programs, driving clonal replacement with (less differentiated) T cells that form T cell:myeloid cell interacting doublets (Visium)/7

Anusha Kalbasi avatar
Anusha Kalbasi@xrtcell·Mar 31

Seq data with empirical support suggests combo may induce T cell responses vs mesenchymal tumor Ags that cross-react with Ags in muscular tissues (sarcoma=mesenchymal). We safely re-introduced aPD1 in 4 patients (fewer doses of BO-112+aPD1). /6

Anusha Kalbasi avatar
Anusha Kalbasi@xrtcell·Mar 31

The kicker: 2 of first 3 pts developed the same myositis-myocarditis-MG picture, an irAE observed rarely with aPD1 alone. We de-escalated and did not observe tox without aPD1. Also no tox with BO-112+aPD1 or aPD1+RT (other studies). Effect seems to require the triple combo. /5

Anusha Kalbasi avatar
Anusha Kalbasi@xrtcell·Mar 31

In mice, intratumoral BO-112 and RT (tumor-only therapy) induces systemic T cell dependent anti-tumor immunity. BO-112 preferentially targets myeloid cells, which works out with RT, which depletes intratumoral lymphocytes but leaves intratumoral myeloid cells intact. /4

Anusha Kalbasi avatar
Anusha Kalbasi@xrtcell·Mar 31

Note: we used hypofrac RT (6 Gy x 5; and no lymph nodes involved), in a regimen we have tested across multiple ph2 studies. /3